OnKure Therapeutics
OKUR
51 hedge funds and large institutions have $49M invested in OnKure Therapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 21 closing their positions.
19% more capital invested
Capital invested by funds: $41.3M → $49M (+$7.67M)
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
4.65% more ownership
Funds ownership: 81.63% → 86.28% (+4.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
23% less funds holding
Funds holding: 66 → 51 (-15)
71% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.52M |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$1.16M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$376K |
| 4 |
Two Sigma Advisers
New York
|
+$224K |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$249K |
| 2 |
Morgan Stanley
New York
|
-$198K |
| 3 |
Goldman Sachs
New York
|
-$193K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$109K |
| 5 |
BlackRock
New York
|
-$107K |
OKUR Hedge Fund Activity: Q3 2024 in Review
51 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2024, worth a combined $49M — up 19% from $41.3M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of OKUR and 6 opened new positions — a net loss of 15 holders — while 14 trimmed existing stakes and 16 added.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.52M. The largest seller was Opaleye Management, exiting entirely with an estimated $249K sold.
- 51 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2024, down from 66 in Q2 2024.
- Funds reported $49M of OnKure Therapeutics stock for Q3 2024, up 19% quarter-over-quarter.
- 6 funds opened new OnKure Therapeutics positions in Q3 2024 and 21 closed out, a net change of -15 holders.
- The largest OnKure Therapeutics buyer in Q3 2024 was Ikarian Capital, an estimated $1.52M added.
- The largest OnKure Therapeutics seller in Q3 2024 was Opaleye Management, an estimated $249K sold.
Based on aggregated 13F filings for Q3 2024.